Concurrent chemoimmunotherapy in metastatic clear cell sarcoma: a case report.
Clear cell sarcoma is a rare tumor with a poor prognosis. The therapeutic approach in the metastatic disease stage is controversial: to the authors' knowledge the use of concurrent chemoimmunotherapy has not been previously reported. We present a case of a 57-year-old male with metastatic clear cell sarcoma treated simultaneously with subcutaneous interferon-a 2b and six courses of chemotherapy according to the CyVEDIC regimen. Disease stabilization lasting 17 months was achieved.
Lauro
S
S
Division of Oncology, La Sapienza University, Rome, Italy.
Bordin
F
F
Trasatti
L
L
Lanzetta
G
G
Della Rocca
C
C
Frati
L
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007866:Leg; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000209:etiology*; D011994:Recombinant Proteins; D018227:Sarcoma, Clear Cell / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015251:Epirubicin; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide